JP2016536361A - Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 - Google Patents

Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 Download PDF

Info

Publication number
JP2016536361A
JP2016536361A JP2016551017A JP2016551017A JP2016536361A JP 2016536361 A JP2016536361 A JP 2016536361A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016536361 A JP2016536361 A JP 2016536361A
Authority
JP
Japan
Prior art keywords
seq
antibody
administration
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536361A5 (enExample
Inventor
カール−ハインツ ハイデル
カール−ハインツ ハイデル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2016536361A publication Critical patent/JP2016536361A/ja
Publication of JP2016536361A5 publication Critical patent/JP2016536361A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016551017A 2013-11-06 2014-11-03 Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 Pending JP2016536361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191839 2013-11-06
EP13191839.3 2013-11-06
PCT/EP2014/073612 WO2015067570A2 (en) 2013-11-06 2014-11-03 Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

Publications (2)

Publication Number Publication Date
JP2016536361A true JP2016536361A (ja) 2016-11-24
JP2016536361A5 JP2016536361A5 (enExample) 2017-12-14

Family

ID=49518850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551017A Pending JP2016536361A (ja) 2013-11-06 2014-11-03 Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物

Country Status (4)

Country Link
US (2) US20150125447A1 (enExample)
EP (1) EP3066125A2 (enExample)
JP (1) JP2016536361A (enExample)
WO (1) WO2015067570A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US11963683B2 (en) 2020-10-02 2024-04-23 Cilag Gmbh International Method for operating tiered operation modes in a surgical system
US11672534B2 (en) 2020-10-02 2023-06-13 Cilag Gmbh International Communication capability of a smart stapler
US12484897B2 (en) 2020-10-02 2025-12-02 Cilag Gmbh International Surgical instrument with adaptive configuration control
US11830602B2 (en) 2020-10-02 2023-11-28 Cilag Gmbh International Surgical hub having variable interconnectivity capabilities
US12472032B2 (en) 2020-10-02 2025-11-18 Cilag Gmbh International Monitoring of user visual gaze to control which display system displays the primary information
US11992372B2 (en) 2020-10-02 2024-05-28 Cilag Gmbh International Cooperative surgical displays
US11877897B2 (en) 2020-10-02 2024-01-23 Cilag Gmbh International Situational awareness of instruments location and individualization of users to control displays
US12580072B2 (en) 2020-10-02 2026-03-17 Cilag Gmbh International Cloud analytics packages
US12016566B2 (en) 2020-10-02 2024-06-25 Cilag Gmbh International Surgical instrument with adaptive function controls
US12064293B2 (en) 2020-10-02 2024-08-20 Cilag Gmbh International Field programmable surgical visualization system
US12213801B2 (en) 2020-10-02 2025-02-04 Cilag Gmbh International Surgical visualization and particle trend analysis system
US11748924B2 (en) 2020-10-02 2023-09-05 Cilag Gmbh International Tiered system display control based on capacity and user operation
CN116948029A (zh) 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045752A1 (en) * 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US7977320B2 (en) * 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045752A1 (en) * 2010-10-04 2012-04-12 Boehringer Ingelheim International Gmbh Cd33 binding agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 122, JPN6018032793, October 2013 (2013-10-01), pages 3959, ISSN: 0004001253 *
MABS, vol. 2, no. 4, JPN6018032792, 2010, pages 440 - 448, ISSN: 0004001252 *

Also Published As

Publication number Publication date
WO2015067570A3 (en) 2015-07-16
US20150125447A1 (en) 2015-05-07
WO2015067570A2 (en) 2015-05-14
US20180064811A1 (en) 2018-03-08
EP3066125A2 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
US20180064811A1 (en) Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
JP7187518B2 (ja) Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン－１８．２を標的にする多重特異性結合タンパク質
AU2018220734B2 (en) Proteins binding CD33, NKG2D and CD16
US20140093499A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
US10946095B2 (en) Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
US20210221894A1 (en) Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
JP2023030174A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
US20190375838A1 (en) Proteins binding bcma, nkg2d and cd16
WO2019055677A1 (en) NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1)
EP3630169A1 (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
US20200024353A1 (en) Proteins binding psma, nkg2d and cd16
BR112021002276A2 (pt) proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
BR112013007944A2 (pt) agentes de ligação ao cd33
US20140093498A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
RU2820629C2 (ru) Полиспецифические связывающие белки, нацеленные на nkg2d, cd16 и trop2
EA051578B1 (ru) Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы
WO2023051674A1 (zh) 联合治疗血液肿瘤的抗cd47抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190322